Journal Of Cancer Research And Clinical Oncology SCIE
國際簡稱：J CANCER RES CLIN 參考譯名：癌癥研究與臨床腫瘤學雜志
主要研究方向：醫(yī)學-腫瘤學 非預警期刊 審稿周期： 約1.0個月
《癌癥研究與臨床腫瘤學雜志》(Journal Of Cancer Research And Clinical Oncology)是一本由Springer Berlin Heidelberg出版的以醫(yī)學-腫瘤學為研究特色的國際期刊，發(fā)表該領域相關的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領域相關理論、實踐和應用學科的最新發(fā)現(xiàn)，旨在促進該學科領域科學信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預警名單。
- 3區(qū) 中科院分區(qū)
- Q3 JCR分區(qū)
- 969 年發(fā)文量
- 2.7 IF影響因子
- 未開放 是否OA
- 87 H-index
- 1904 創(chuàng)刊年份
- Monthly 出版周期
- English 出版語言
The "Journal of Cancer Research and Clinical Oncology" publishes significant and up-to-date articles within the fields of experimental and clinical oncology. The journal, which is chiefly devoted to Original papers, also includes Reviews as well as Editorials and Guest editorials on current, controversial topics. The section Letters to the editors provides a forum for a rapid exchange of comments and information concerning previously published papers and topics of current interest. Meeting reports provide current information on the latest results presented at important congresses.
The following fields are covered: carcinogenesis - etiology, mechanisms; molecular biology; recent developments in tumor therapy; general diagnosis; laboratory diagnosis; diagnostic and experimental pathology; oncologic surgery; and epidemiology.
Journal Of Cancer Research And Clinical Oncology期刊信息
- ISSN：0171-5216
- 出版語言：English
- 是否OA：未開放
- E-ISSN：1432-1335
- 出版地區(qū)：GERMANY
- 是否預警：否
- 出版商：Springer Berlin Heidelberg
- 出版周期：Monthly
- 創(chuàng)刊時間：1904
- 開源占比：0.366
- Gold OA文章占比：35.02%
- OA被引用占比：0.1835...
- 出版國人文章占比：0.24
- 出版撤稿占比：0
- 研究類文章占比：89.06%
Journal Of Cancer Research And Clinical Oncology CiteScore評價數(shù)據(jù)（2024年最新版）
| CiteScore | SJR | SNIP | CiteScore 指數(shù) | ||||||||||||
| 4 | 1.023 | 0.953 |
|
名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標。當年CiteScore 的計算依據(jù)是期刊最近4年（含計算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻數(shù)。例如，2022年的 CiteScore 計算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻數(shù)量 注：文獻類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。
Journal Of Cancer Research And Clinical Oncology中科院評價數(shù)據(jù)
中科院 2023年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 3區(qū) | ONCOLOGY 腫瘤學 | 4區(qū) |
中科院 2022年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 3區(qū) | ONCOLOGY 腫瘤學 | 3區(qū) |
中科院 2021年12月舊的升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 3區(qū) | ONCOLOGY 腫瘤學 | 3區(qū) |
中科院 2021年12月基礎版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 3區(qū) | ONCOLOGY 腫瘤學 | 3區(qū) |
中科院 2021年12月升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 3區(qū) | ONCOLOGY 腫瘤學 | 3區(qū) |
中科院 2020年12月舊的升級版
| Top期刊 | 綜述期刊 | 大類學科 | 小類學科 | ||
| 否 | 否 | 醫(yī)學 | 2區(qū) | ONCOLOGY 腫瘤學 | 3區(qū) |
Journal Of Cancer Research And Clinical Oncology JCR評價數(shù)據(jù)（2023-2024年最新版）
| 按JIF指標學科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
| 學科：ONCOLOGY | SCIE | Q3 | 163 / 322 |
49.5% |
| 按JCI指標學科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
| 學科：ONCOLOGY | SCIE | Q3 | 172 / 322 |
46.74% |
Journal Of Cancer Research And Clinical Oncology歷年數(shù)據(jù)統(tǒng)計
影響因子
中科院分區(qū)
Journal Of Cancer Research And Clinical Oncology中國學者發(fā)文選摘
-
1、Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study
Author: Lin, Xinqing; Deng, Haiyi; Li, Suyang; Xie, Xiaohong; Chen, Chao; Cai, Longqiu; Yang, Yilin; Qiu, Guihuan; Xie, Zhanhong; Qin, Yinyin; Liu, Ming; Zhou, Chengzhi
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 757-764. DOI: 10.1007/s00432-021-03903-0
-
2、Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Author: Cao, Yanshuo; Lu, Ming; Sun, Yu; Gong, Jifang; Li, Jie; Lu, Zhihao; Li, Jian; Zhang, Xiaotian; Li, Yan; Peng, Zhi; Zhou, Jun; Wang, Xicheng; Shen, Lin
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 779-789. DOI: 10.1007/s00432-021-03898-8
-
3、Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial
Author: Sun, Chao; Liu, Yunpeng; Zhang, Peng; Wang, Xu; Xu, Yinghui; Lin, Xingyu; Ma, Xiaobo; Guo, Ye; Qiu, Shi; Shao, Guoguang; Yang, Zhiguang; Ma, Kewei
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 819-831. DOI: 10.1007/s00432-021-03896-w
-
4、Analysis of online plan adaptation for 1.5T magnetic resonance-guided stereotactic body radiotherapy (MRgSBRT) of prostate cancer
Author: Poon, Darren M. C.; Yang, Bin; Geng, Hui; Wong, Oi Lei; Chiu, Sin Ting; Cheung, Kin Yin; Yu, Siu Ki; Chiu, George; Yuan, Jing
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 2, pp. 841-850. DOI: 10.1007/s00432-022-03950-1
-
5、Comparison of clinical characteristics, treatment efficacy and survival in patients with newly diagnosed multiple myeloma with single- versus multi-site extramedullary invasion
Author: Zhao, Yongfeng; Zhou, Fuling
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 995-1006. DOI: 10.1007/s00432-022-03948-9
-
6、The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients
Author: Wu, Guowu; Guo, Longhua; Gu, Yinfang; Huang, Tanxiao; Liu, Ming; Zou, Xiaofang; Yang, Bo; Huang, Ping; Wen, Chunling; Yi, Lilan; Liao, Wenting; Zhao, Dongdong; Zhu, Junlin; Zhang, Xiaoni; Liu, Yuanyuan; Yin, Yan; Chen, Shifu
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1019-1028. DOI: 10.1007/s00432-022-03959-6
-
7、Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis
Author: Zhang, Shuwen; Chen, Jingjing; Zhang, Rui; Xu, Liqin; Wang, Yan; Yuan, Zaixin; Hou, Xiaohui; Feng, Jian
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1063-1077. DOI: 10.1007/s00432-022-03970-x
-
8、Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer
Author: Du, Wei; Chen, Chen; Lin-feng Luo; Li-na He; Wang, Yixing; Zhang, Xuanye; Zhou, Yixin; Lin, Zuan; Hong, Shaodong
Journal: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023; Vol. 149, Issue 3, pp. 1103-1113. DOI: 10.1007/s00432-022-03978-3
Journal Of Cancer Research And Clinical Oncology同類期刊
-
公共衛(wèi)生前沿
Frontiers In Public Health
中科院 3區(qū) JCR Q2
-
藥理學前沿
Frontiers In Pharmacology
中科院 2區(qū) JCR Q1
-
生物醫(yī)學與藥物治療
Biomedicine & Pharmacotherapy
中科院 2區(qū) JCR Q1
-
探索腫瘤學
Discover Oncology
中科院 4區(qū) JCR Q2
-
Bmc精神病學
Bmc Psychiatry
中科院 2區(qū) JCR Q2
-
Bmc神經(jīng)病學
Bmc Neurology
中科院 3區(qū) JCR Q3
-
材料化學雜志 B
Journal Of Materials Chemistry B
中科院 3區(qū) JCR Q1
-
美康
Medcomm
中科院 3區(qū) JCR Q1
免責聲明
若用戶需要出版服務，請聯(lián)系出版商：SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013。